 Vaccitech plc NASDAQ: VACC has announced an interim analysis of safety and efficacy data of VTP-300 from the HBV002 study, including a review of surface antigen HBsAg levels in chronic Hepatitis B patients. Data from an interim analysis of immunogenicity and safety in Groups 1 and 2 were recently reported at the 2021 AASLD The Liver Meeting. 